Literature DB >> 24275269

HPV and HPV-associated diseases.

Eileen F Dunne1, Ina U Park.   

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection. HPV is associated with a significant burden of disease and cancer, including anogenital warts and recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. Effective prevention is available, including primary prevention of cancers and anogenital warts through HPV vaccination, and secondary prevention of cervical cancer through screening and treatment of precancer. This article focuses on HPV infection and the clinical consequences of infection, with attention to cervical and anogenital squamous intraepithelial neoplasia and anogenital warts. Published by Elsevier Inc.

Entities:  

Keywords:  Anogenital warts; Cervical cancer; Genital warts; HPV; HPV vaccines; HPV-associated diseases

Mesh:

Year:  2013        PMID: 24275269     DOI: 10.1016/j.idc.2013.09.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  34 in total

1.  Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines.

Authors:  Jin-Ling Yi; Song Shi; Yan-Li Shen; Ling Wang; Hai-Yan Chen; Jun Zhu; Yan Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  HLA and KIR Associations of Cervical Neoplasia.

Authors:  Xiao Bao; Aimee L Hanson; Margaret M Madeleine; Sophia S Wang; Stephen M Schwartz; Felicity Newell; Ulrika Pettersson-Kymmer; Kari Hemminki; Sven Tiews; Winfried Steinberg; Janet S Rader; Felipe Castro; Mahboobeh Safaeian; Eduardo L Franco; François Coutlée; Claes Ohlsson; Adrian Cortes; Mhairi Marshall; Pamela Mukhopadhyay; Katie Cremin; Lisa G Johnson; Suzanne M Garland; Sepehr N Tabrizi; Nicolas Wentzensen; Freddy Sitas; Cornelia Trimble; Julian Little; Maggie Cruickshank; Ian H Frazer; Allan Hildesheim; Matthew A Brown; Emma L Duncan; Ying Pu Sun; Paul J Leo
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Promoting intolerance: learning from warts.

Authors:  S Rao; J L Arbiser
Journal:  Br J Dermatol       Date:  2017-09       Impact factor: 9.302

4.  microRNA-195 inhibits the proliferation, migration and invasion of cervical cancer cells via the inhibition of CCND2 and MYB expression.

Authors:  Xinjie DU; L I Lin; Lijun Zhang; Jie Jiang
Journal:  Oncol Lett       Date:  2015-07-29       Impact factor: 2.967

5.  The E6-TAp63β-Dicer feedback loop involves in miR-375 downregulation and epithelial-to-mesenchymal transition in HR-HPV+ cervical cancer cells.

Authors:  Hongzhi Lu; Zhengqin Qi; Lin Lin; Li Ma; Li Li; Hong Zhang; Li Feng; Ying Su
Journal:  Tumour Biol       Date:  2016-11-03

6.  The process of engaging members from two underserved populations in the development of interventions to promote the uptake of the HPV vaccine.

Authors:  Mira L Katz; Electra D Paskett
Journal:  Health Promot Pract       Date:  2014-11-24

7.  PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians.

Authors:  Yan Chen; Zhaolei Cui; Zhenzhou Xiao; Minhua Hu; Chuanhui Jiang; Yingying Lin; Yansong Chen
Journal:  Ann Transl Med       Date:  2016-10

8.  Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients.

Authors:  Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Stephanie B Wheeler; Stacie B Dusetzina
Journal:  Am J Public Health       Date:  2018-05-17       Impact factor: 9.308

9.  Oncogenic Human Papillomavirus Infections in 18- to 24-Year-Old Female Online Daters.

Authors:  Alexis Barrere; Joshua E Stern; Qinghua Feng; James P Hughes; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2015-09       Impact factor: 2.830

10.  Racial disparities in routine health checkup and adherence to cancer screening guidelines among women in the United States of America.

Authors:  Amarachukwu F Orji; Takashi Yamashita
Journal:  Cancer Causes Control       Date:  2021-07-03       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.